相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
50.0%
尚未招募
1
25.0%
撤回
1
25.0%
暂无批准数据
- The Ohio State University's Center for Psychedelic Drug Research and Education received a $400,000 grant to train over 127,000 Ohio healthcare professionals in psychedelic harm reduction and crisis response. - The P.E.A.C.E. program addresses rising psychedelic use, which increased from 2.7% to 3.6% of Americans aged 12 and older between 2021 and 2024 according to national survey data. - The initiative collaborates with MAPS to provide specialized training modules for emergency responders, law enforcement, and behavioral health professionals on psychedelic crisis recognition and response. - Training seminars will be offered at no cost in January, March, and July 2026 to ensure Ohio's workforce has evidence-based tools for managing psychedelic-related emergencies.
- The FDA has approved a study examining cannabis's therapeutic effects on 320 veterans with moderate to severe PTSD, a condition affecting roughly 7% of U.S. veterans. - The study, funded by the Michigan Veteran Marijuana Research Grant Program, will investigate inhaled high-THC cannabis flower versus placebo, with participants self-adjusting the daily dose. - The research aims to address the lack of high-quality data on cannabis's safety and effectiveness for PTSD, despite its widespread use for medical purposes in many states. - Positive results could lead to broader cannabis use for PTSD treatment and potentially benefit the cannabis sector, while negative outcomes could hinder its advancement.
- The FDA has approved a study examining cannabis's therapeutic potential for treating post-traumatic stress disorder (PTSD) in 320 veterans. - The study, funded by the Michigan Veteran Marijuana Research Grant Program, will investigate inhaled high-THC cannabis flower versus a placebo. - The FDA's decision marks a rare move, as cannabis remains a Schedule I drug at the federal level, highlighting the need for alternative PTSD treatments. - The research aims to provide high-quality data on cannabis's safety and effectiveness for PTSD, potentially influencing future treatment approaches.
- The FDA has approved a Phase 2 clinical trial to evaluate smoked marijuana for treating PTSD in veterans, funded by Michigan cannabis sales tax revenue. - The trial, involving 320 veterans with moderate to severe PTSD, will study the effects of inhaled high-THC cannabis versus placebo, self-titrated by participants. - This study aims to provide data on the real-world use of cannabis for PTSD, addressing the lack of rigorous research on its efficacy and potential benefits. - The approval follows three years of negotiations with the FDA, overcoming obstacles related to THC dosage, delivery methods, and participant criteria.
- The FDA has cleared a Phase 2 trial to evaluate smoked cannabis in 320 veterans with moderate-to-severe PTSD who have prior cannabis use. - The trial will assess the safety and efficacy of inhaled THC-dominant dried cannabis flower compared to placebo in alleviating PTSD symptoms. - Previous research suggests THC may act on brain receptors involved in memory and fear, potentially reducing inflammation associated with PTSD. - The study addresses a critical need for new PTSD treatments, as over 23% of military service members experience the condition.
